Diabetes Drugs Market Size, Share and Industry Analysis By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Regional Forecast 2019 - 2026

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Prevalence of Diabetes - For Key Countries, 2018

4.2 Pipeline Analysis

4.3 Key Industry Developments –Mergers, Acquisitions and Partnerships

4.4 Introduction of New Drugs/Approvals (by major players)

4.5 Overview of Regulatory Scenario of Key Countries/ Regions

5. Global Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Insulin

5.2.2 DPP-4 Inhibitors

5.2.3 GLP-1 Receptor Agonists

5.2.4 SGLT2 Inhibitors

5.2.5 Others

5.3. Market Analysis, Insights and Forecast – By Diabetes Type

5.3.1 Diabetes 1

5.3.2 Diabetes 2

5.4 Market Analysis, Insights and Forecast – By Route of Administration

5.4.1 Oral

5.4.2 Subcutaneous

5.4.3 Intravenous

5.5. Market Analysis, Insights and Forecast – By Distribution Channel

5.5.1 Online pharmacies

5.5.2 Hospital Pharmacies

5.5.3 Retail Pharmacies

5.6. Market Analysis, Insights and Forecast – By Region

5.6.1 North America

5.6.2 Europe

5.6.3 Asia Pacific

5.6.4 Latin America

5.6.5 Middle East & Africa

6. North America Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis, Insights and Forecast – By Drug Class

6.2.1 Insulin

6.2.2 DPP-4 Inhibitors

6.2.3 GLP-1 Receptor Agonists

6.2.4 SGLT-2 Inhibitors

6.2.5 Others

6.3. Market Analysis, Insights and Forecast – By Diabetes Type

6.3.1 Diabetes 1

6.3.2 Diabetes 2

6.4. Market Analysis, Insights and Forecast – By Route of Administration

6.4.1 Oral

6.4.2 Subcutaneous

6.4.3 Intravenous

6.5. Market Analysis, Insights and Forecast – By Distribution Channel

6.5.1 Online pharmacies

6.5.2 Hospital Pharmacies

6.5.3 Retail Pharmacies

6.6. Market Analysis, Insights and Forecast – By Country

6.6.1 U.S.

6.6.2 Canada

7. Europe Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis, Insights and Forecast – By Drug Class

7.2.1 Insulin

7.2.2 DPP-4 Inhibitors

7.2.3 GLP-1 Receptor Agonists

7.2.4 SGLT-2 Inhibitors

7.2.5 Others

7.3. Market Analysis, Insights and Forecast – By Diabetes Type

7.3.1 Diabetes 1

7.3.2 Diabetes 2

7.4. Market Analysis, Insights and Forecast – By Route of Administration

7.4.1 Oral

7.4.2 Subcutaneous

7.4.3 Intravenous

7.5. Market Analysis, Insights and Forecast – By Distribution Channel

7.5.1 Online pharmacies

7.5.2 Hospital Pharmacies

7.5.3 Retail Pharmacies

7.6. Market Analysis, Insights and Forecast – By Country/ Sub-region

7.6.1 UK

7.6.2 Germany

7.6.3 France

7.6.4 Italy

7.6.5 Spain

7.6.6 Scandinavia

7.6.7 Rest of Europe

8. Asia Pacific Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis, Insights and Forecast – By Drug Class

8.2.1 Insulin

8.2.2 DPP-4 Inhibitors

8.2.3 GLP-1 Receptor Agonists

8.2.4 SGLT-2 Inhibitors

8.2.5 Others

8.3. Market Analysis, Insights and Forecast – By Diabetes Type

8.3.1 Diabetes 1

8.3.2 Diabetes 2

8.4. Market Analysis, Insights,and Forecast – By Route of Administration

8.4.1 Oral

8.4.2 Subcutaneous

8.4.3 Intravenous

8.5. Market Analysis, Insights and Forecast – By Distribution Channel

8.5.1 Online pharmacies

8.5.2 Hospital Pharmacies

8.5.3 Retail Pharmacies

8.6. Market Analysis, Insights and Forecast – By Country/ Sub-region

8.6.1 China

8.6.2 India

8.6.3 Japan

8.6.4 Australia

8.6.5 South East Asia

8.6.6 Rest of Asia Pacific

9. Latin America Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis, Insights and Forecast – By Drug Class

9.2.1 Insulin

9.2.2 DPP-4 Inhibitors

9.2.3 GLP-1 Receptor Agonists

9.2.4 SGLT-2 Inhibitors

9.2.5 Others

9.3. Market Analysis, Insights and Forecast – By Diabetes Type

9.3.1 Diabetes 1

9.3.2 Diabetes 2

9.4. Market Analysis, Insights and Forecast – By Route of Administration

9.4.1 Oral

9.4.2 Subcutaneous

9.4.3 Intravenous

9.5. Market Analysis, Insights and Forecast – By Distribution Channel

9.5.1 Online pharmacies

9.5.2 Hospital Pharmacies

9.5.3 Retail Pharmacies

9.6. Market Analysis, Insights and Forecast – By Country/ Sub-region

9.6.1 Brazil

9.6.2 Mexico

9.6.3 Rest of Latin America

10. Middle East &Africa Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis, Insights and Forecast – By Drug Class

10.2.1 Insulin

10.2.2 DPP-4 Inhibitors

10.2.3 GLP-1 Receptor Agonists

10.2.4 SGLT-2 Inhibitors

10.2.5 Others

10.3. Market Analysis, Insights,and Forecast – By Diabetes Type

10.3.1 Diabetes 1

10.3.2 Diabetes 2

10.4. Market Analysis, Insights,and Forecast – By Route of Administration

10.4.1 Oral

10.4.2 Subcutaneous

10.4.3 Intravenous

10.5. Market Analysis, Insights,and Forecast – By Distribution Channel

10.5.1 Online pharmacies

10.5.2 Hospital Pharmacies

10.5.3 Retail Pharmacies

10.6. Market Analysis, Insights,and Forecast – By Country/ Sub-region

10.6.1 GCC

10.6.2 South Africa

10.6.3 Rest of Middle East and Africa

11. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2018)

11.3. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.3.1 Novo Nordisk India Pvt Ltd

11.3.2 Sanofi

11.3.3 Merck& Co., Inc.

11.3.4 Eli Lilly and Company.

11.3.5 Astra Zeneca

11.3.6 Takeda Pharmaceutical Company Limited

11.3.7 Boehringer Ingelheim International GmbH

11.3.8 Novartis AG

11.3.9 Johnson & Johnson Services, Inc.

11.3.10 Bayer AG

11.3.11 Other Players